Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion plus Non-Small-Cell Lung Cancer (NSCLC)

被引：0
作者：
Gainor, J. F. [1 ]
Curigliano, G. [2 ]
Kim, D. -W. [3 ]
Lee, D. H. [4 ]
Besse, B. [5 ]
Baik, C. S. [6 ]
Doebele, R. C. [7 ]
Cassier, P. [8 ]
Lopes, G. [9 ]
Tan, D. S. -W. [10 ]
Garralda, E. [11 ]
Paz-Ares, L. [12 ]
Cho, B. C. [13 ]
Gadgeel, S. M. [14 ]
Thomas, M. [15 ]
Liu, S. V. [16 ]
Clifford, C. [17 ]
Zhang, H. [17 ]
Turner, C. D. [17 ]
Subbiah, V. [18 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Univ Milan, European Inst Oncol, IRCCS, Milan, Italy
[3] Seoul Natl Univ Hosp, Seoul, South Korea
[4] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[5] Gustave Roussy Univ Paris Sud, Villejuif, France
[6] Univ Washington, Sch Med, Main Hosp Seattle, Seattle, WA 98195 USA
[7] Univ Colorado, Canc Ctr, Aurora, CO USA
[8] Ctr Leon Berard, Lyon, France
[9] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[10] Natl Canc Ctr Singapore, Singapore, Singapore
[11] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[12] Hosp Univ 12 Octubre, Madrid, Spain
[13] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[14] Henry Ford Canc Inst, Detroit, MI USA
[15] Heidelberg Univ Hosp, Thoraxklin, Heidelberg, Germany
[16] Georgetown Univ, Washington, DC USA
[17] Blueprint Med Corp, Cambridge, MA USA
[18] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO01.38
引用
收藏
页码：S31 / S32
页数：2
相关论文
共 50 条
  • [41] Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Mohamed N. M. T. Al Khayat
    Nigel Armstrong
    Jeremy Howick
    Susan O’Meara
    Pawel Posadzki
    Steve Ryder
    Charlotte Ahmadu
    Stefan R. A. Konings
    Maarten J. Postma
    Steven Duffy
    Robert F. Wolff
    Antoinette D. I. van Asselt
    PharmacoEconomics, 2023, 41 : 353 - 361
  • [42] Gefitinib plus interleukin-2 in previously treated patients with advanced non-small-cell lung cancer (NSCLC)
    Longarini, Raffaella
    Buti, Sebastiano
    Bosio, Giancarlo
    Brighenti, Matteo
    Porzio, Rosa
    Negri, Federica
    Passalacqua, Rodolfo
    ANNALS OF ONCOLOGY, 2007, 18 : 30 - 30
  • [43] Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Al Khayat, Mohamed N. M. T.
    Armstrong, Nigel
    Howick, Jeremy
    O'Meara, Susan
    Posadzki, Pawel
    Ryder, Steve
    Ahmadu, Charlotte
    Konings, Stefan R. A.
    Postma, Maarten J.
    Duffy, Steven
    Wolff, Robert F.
    van Asselt, Antoinette D. I.
    PHARMACOECONOMICS, 2023, 41 (04) : 353 - 361
  • [44] An overview of phase II trial results - Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer
    DeVore, R
    Johnson, D
    Crawford, J
    Dimery, I
    Eckardt, J
    Eckhardt, SG
    ONCOLOGY-NEW YORK, 1998, 12 (08): : 79 - 83
  • [45] Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer
    Isla, D
    Rosell, R
    Sánchez, JJ
    Carrato, A
    Felip, E
    Camps, C
    Artal, A
    González-Larriba, JL
    Azagra, P
    Alberola, J
    Martin, C
    Massutí, B
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) : 1071 - 1077
  • [46] A phase II study of oxaliplatin and docetaxel in patients with advanced non-small-cell lung cancer (NSCLC)
    Raez, L
    Santos, E
    Rocha-Lima, C
    Roman, E
    Kumar, P
    Farfan, N
    Decesare, T
    Lopes, G
    Rosado, M
    Wu, J
    LUNG CANCER, 2005, 49 : S265 - S265
  • [47] Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC):: An AASLC phase II trial
    Krajnik, G
    Mohn-Staudner, A
    Thaler, J
    Greil, R
    Schmeikal, S
    Marhold, F
    Deutsch, J
    Preiss, P
    Malayeri, R
    Schäfer-Prokop, C
    Wein, W
    Huber, H
    Pirker, R
    ANNALS OF ONCOLOGY, 2000, 11 (08) : 993 - 998
  • [48] Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion plus non-small cell lung cancer (NSCLC)
    Drilon, A.
    Subbiah, V.
    Gautschi, O.
    Tomasini, P.
    De Braud, F. G. M.
    Solomon, B.
    Tan, D. Shao-Weng
    Alonso, G.
    Wolf, J.
    Park, K.
    Goto, K.
    Soldatenkova, V.
    Szymczak, S.
    Barker, S.
    Puri, T.
    Lin, A. B.
    Loong, H. H. F.
    Besse, B.
    ANNALS OF ONCOLOGY, 2022, 33 : S43 - S43
  • [49] Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)
    Valerie Israel
    Scott T. Tagawa
    Terry Snyder
    Susan Jeffers
    Derek Raghavan
    Investigational New Drugs, 2004, 22 : 291 - 297
  • [50] Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)
    Israel, V
    Tagawa, ST
    Snyder, T
    Jeffers, S
    Raghavan, D
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (03) : 291 - 297
12345